Synthesis, Characterization, and Bioactivity of Quinoxaline Thiazolotriazoles
Journal of Heterocyclic Chemistry · 2025-11 · 62 (11) · 1698-1707
DOI: 10.1002/jhet.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Heterocyclic Chemistry, online erschienen am 10.09.2025. Verfasst von Silungile Mhlongo und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A total of 10 quinoxaline thiazolo[2,3‐c][1,2,4]triazole hybrid molecules were synthesized in a four‐step synthetic protocol. Six of these compounds are reported here for the first time. All the synthesized molecules were characterized by various spectroscopic techniques and evaluated for their in vitro antibacterial, antidiabetic, anti‐TB, and anticancer properties. Thiazolo[2,3‐c][1,2,4]triazoles have been reported to have a wide range of biological applications. Antibacterial screening showed that although the compounds were not as active as the standard compounds, 4a (unsubstituted derivative) and 4g (cyano derivative) had broad spectrum activity, being active against five and six strains, respectively, with MICs between 94–379 and 176–352 μM. Compound 4i , the naphthyl derivative, had an MIC of 164 μM against three strains, E. coli , P. aeruginosa , and S. pyogenes . The compounds were not active against α‐glucosidase, but five of the compounds, 4c , 4e , 4g , 4i , and 4j , were active against α‐amylase with IC 50 values between 186 and 293 μM. The most active compound was 4g (IC 50 = 186 μM). With the exception of the naphthyl compound 4i , all compounds showed good antitubercular activity inhibiting the growth of Mycobacterium tuberculosis with MICs between 83 and 96 μM, being 2‐fold less active than erythromycin, which had an MIC of 42 μM in the same assay. None of the compounds showed activity against HepG2, HeLa, and Caco2 cancer cell lines. Compound 4g , the cyano derivative, emerged as the most active compound of the series, showing both antibacterial and antidiabetic activity.
Zitieren
APA
Mhlongo, S., Senzani, S., Islam, S., Olofinsan, K., Singh, M., Nundkumar, N., Mokoena, S., Karpoormath, R., & Koorbanally, N. A. (2025). Synthesis, Characterization, and Bioactivity of Quinoxaline Thiazolotriazoles. Journal of Heterocyclic Chemistry, 62(11), 1698-1707. https://doi.org/10.1002/jhet.70093
Vancouver
Mhlongo S, Senzani S, Islam S, Olofinsan K, Singh M, Nundkumar N, et al. Synthesis, Characterization, and Bioactivity of Quinoxaline Thiazolotriazoles. Journal of Heterocyclic Chemistry. 2025;62(11):1698-1707. doi:10.1002/jhet.70093
BibTeX
@article{Mhlongo2025,
author = {Mhlongo, Silungile and Senzani, Sibusiso and Islam, Shahidul and Olofinsan, Kolawole and Singh, Moganavelli and Nundkumar, Nirasha and Mokoena, Sithabile and Karpoormath, Rajshekhar and Koorbanally, Neil A.},
title = {Synthesis, Characterization, and Bioactivity of Quinoxaline Thiazolotriazoles},
journal = {Journal of Heterocyclic Chemistry},
year = {2025},
volume = {62},
number = {11},
pages = {1698--1707},
doi = {10.1002/jhet.70093}
}
EUVIMED